Peter Greenleaf
CIK 1363683 · Chief Executive Officer · last filed 2026-04-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$31.39M
Companies
10
Total Filings
58
Lifetime Open-Market Net
-$7.55M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PTHS | Director | 24,681 | $27.50 | $678.7K | -$16.7K | 3 | 2026-04-06 |
| AUPH | Chief Executive Officer | 1,941,269 | $15.82 | $30.71M | -$4.22M | 10 | 2026-03-03 |
| ANTARES PHARMA, INC. (ATRS) Delisted | Director | 79,645 | $5.59 | $445.2K | $0 | 4 | 2021-06-14 |
| Avalo Therapeutics, Inc. (CERC) Delisted | Chief Executive Officer | 112,500 | $2.93 | $329.6K | $0 | 3 | 2019-10-03 |
| EYEG | Director | — | $35.27 | — | $0 | 2 | 2019-02-05 |
| Avalo Therapeutics, Inc. (CERCW) Delisted | Chief Executive Officer | 412,500 | — | — | $49.8K | 4 | 2018-05-21 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Chief Executive Officer | 0 | — | — | -$3.37M | 16 | 2018-02-13 |
| MSTX | Director | — | $16.18 | — | $0 | 3 | 2017-01-23 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | — | — | — | $0 | 3 | 2016-09-06 |
| MEDI | SVP, Sales and Marketing | — | $31.04 | — | $0 | 2 | 2007-06-19 |
Recent Filings · Page 2 of 6
58 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-03-06 | AUPH | Mixed | +634,657 | -$292.8K | EDGAR |
| 2022-05-26 | — | Disp (D) | −79,645 | -$446.0K | |
| 2022-03-22 | — | Mixed | −105,034 | $0 | |
| 2022-03-04 | AUPH | Mixed | +19,232 | -$108.9K | EDGAR |
| 2022-01-31 | — | Mixed | +10,246 | $0 | |
| 2021-08-10 | — | Exer (M) | +35,000 | $0 | |
| 2021-06-14 | ANTARES PHARMA, INC. (ATRS) Delisted | Grant (A) | +25,452 | $112.5K | EDGAR |
| 2021-05-12 | AUPH | Buy (P) | +5,125 | $54.9K | EDGAR |
| 2020-08-11 | — | Exer (M) | +35,000 | $0 | |
| 2020-06-15 | ANTARES PHARMA, INC. (ATRS) Delisted | Grant (A) | +30,220 | $82.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.